Drug Trial Radar · NCT07921576
Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jun 16, 2028
Study completion Aug 15, 2028
Sponsor
- Lead sponsor
- Dartsbio Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia
Conditions
- Cancer
- Cachexia
Interventions
DS010 injectionDrug
Once every 3 weeks intravenously injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Dose-limiting toxicity (DLT)Time frame: 21 days after the first dose
- Phase 1: Incidence of adverse events as assessed by CTCAE V6.0Time frame: Up to 20 weeks
- Phase 2: Change in body weight from baseline to Week 12Time frame: Baseline, Week 12
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Concord Cancer Centre Medical Oncology Clinical Trials Unit
Concord West, New South Wales, Australia · Recruiting
Cancer Care Northern Beache
Frenchs Forest, New South Wales, Australia · Recruiting
Southside Cancer Care Centre
Miranda, New South Wales, Australia · Recruiting
Peninsula and Southeast Oncology (PASO)
Frankston, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.